The relative efficacy of hormonal, chemical, or combined therapy was investigated in a prostate cancer animal model. 96 Copenhagen-Fischer hybrid rats were implanted with equal-sized fragments of the Dunning H strain transplantable prostatic adenocarcinoma. These animals were randomly assigned to 1 of 6 treatment groups: (1) control, (2) testosterone, (3) testosterone followed by cyclophosphamide, (4) cyclophosphamide, (5) orchiectomy or (6) orchiectomy followed by cyclophosphamide. Animals in the control group had the shortest survival, fastest tumor growth rate, and largest tumor size. Testosterone, when compared to the control group, did not accelerate tumor growth. Cyclophosphamide alone, orchiectomy alone, cyclophosphamide plus orchiectomy, and testosterone plus cyclophosphamide were each equally effective in decreasing tumor growth rate. Tumor size in the testosterone plus cyclophosphamide-treated animals was equivalent to that in orchiectomized animals. The survival of all groups treated with cyclophosphamide was reduced because of toxicity. Testosterone administered prior to cyclophosphamide eliminated and shortened survival from cyclophosphamide. The best overall results were obtained by orchiectomy alone, orchiectomy plus cyclophosphamide, and testosterone plus cyclophosphamide. Although chemotherapy alone was effective in shrinking tumor size, it was highly toxic.

Keywords:
Prostate cancer, Chemotherapy, Hormonal therapy, Dunning tumor
This content is only available via PDF.
© 1985 S. Karger AG, Basel
1985
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.